ABUS vs TPR · P/E 5.4, rev $6.2M vs P/E 46, rev $8.00B
Arbutus Biopharma Corp (ABUS) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the ABUS and TPR stock pages for the full models.
Not investment advice.